BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

L Number	Hits	Search Text	DB	Time stamp
1	50	"0028682"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 16:32
2	0	"000028682"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 16:32
3	105	"28682"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 16:32
4	4	"1602290"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 16:32
-	7	"6071970"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 09:29
-	1	"54039057"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 09:29
-	4	"1602290"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 09:32
-	487	mueller.in. and (antidepress$ or (anti near depress$) or depress$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 10:48
-	294	mueller.in. and (antidepress$ or (anti near depress$) or depress$) and @pd<19980713	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:18
-	2	mueller.in. and (antidepress$ or (anti near depress$) or depress$) and @pd<19980713 and nmda	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 10:51
-	11	mueller.in. and (antidepress$ or (anti near depress$) or depress$) and nmda	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 10:59
-	0	mueller.in. and (antidepress$ or (anti near depress$) or depress$).clm. and nmda	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 10:59
-	4	"1602290"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:02

-	7	"7802093"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:02
-	39	"64963"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:02
-	37	"64936"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:03
-	7	"7802951"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:03
-	0	"7837612"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:03
-	12	"519960"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:04
-	10	"1111041"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:04
-	8	"7802305"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:05
-	23	"146743"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:05
-	7	"7804835"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:06
-	6	"363456"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:06
-	105	"28682"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:07
-	2	"28682" and antidepress$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:08

-	7	"8004933"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:08
-	13	"368988"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:08
-	440213	(antidepress$ or (anti near depress$) or depress$) nmda nad seratonin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:18
-	428721	(antidepress$ or (anti near depress$) or depress$) nmda and seratonin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:19
-	3	(antidepress$ or (anti near depress$) or depress$) and nmda and seratonin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/05 11:19
-	429025	(depress$ or antidepress$).ab and nmda.ab. and serotonin.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 14:50
-	11	(depress$ or antidepress$).ab. and nmda.ab. and serotonin.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 14:51
-	58	((depress$ or antidepress$) same nmda same serotonin) not ((depress$ or antidepress$).ab. and nmda.ab. and serotonin.ab.)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 14:52
-	7	(((depress$ or antidepress$) same nmda same serotonin) not ((depress$ or antidepress$).ab. and nmda.ab. and serotonin.ab.)) and (depress$.ab. or antidepress$.ab.)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 14:52
-	62	(depress$ or antidepress$) same nmda same serotonin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 15:01
-	535	(depress$ or antidepress$) same nmda	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 15:02
-	111	(depress$ or antidepress$) same nmda.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 15:15
-	546	nmda AND serotonin AND (depress$ OR antidepress$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 15:16

-	148	nmda AND serotonin AND (depress$ OR antidepress$).clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 15:16
-	15	nmda.clm. AND serotonin.clm. AND (depress$ OR antidepress$).clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/11/06 16:31

L5 ANSWER 1 OF 5 CA COPYRIGHT 2003 ACS on STN DUPLICATE 1
AN 133:30571 CA
TI Preparation of aralkylamines active at receptor-operated calcium channels as neuroprotectants
IN Mueller, Alan L.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Moe, Scott T.; Artman, Linda D.; Barmore, Robert M.
PA NPS Pharmaceuticals, Inc., USA
SO U.S., 133 pp., Cont.-in-part of WO 9511663.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6071970	A	20000606	US 1995-485038	19950607
	CA 2182680	AA	19950817	CA 1994-2182680	19941026
	WO 9521612	A2	19950817	WO 1994-US12293	19941026
	WO 9521612	A3	19950921		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CN 1148337	A	19970423	CN 1994-195074	19941026
	CN 1088585	B	20020807		
	ES 2156162	T3	20010616	ES 1994-932057	19941026
	EP 1123922	A2	20010816	EP 2000-121960	19941026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	CA 2223978	AA	19961219	CA 1996-2223978	19960607
	WO 9640097	A1	19961219	WO 1996-US10201	19960607
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9661125	A1	19961230	AU 1996-61125	19960607
	AU 716122	B2	20000217		
	EP 831799	A1	19980401	EP 1996-918477	19960607
	EP 831799	B1	20030502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1192679	A	19980909	CN 1996-196042	19960607
	JP 11506469	T2	19990608	JP 1996-502238	19960607
	BR 9609019	A	19990706	BR 1996-9019	19960607
	NZ 310344	A	20010330	NZ 1996-310344	19960607
	AT 238782	E	20030515	AT 1996-918477	19960607
	PL 185492	B1	20030530	PL 1996-323871	19960607
	US 6017965	A	20000125	US 1996-763480	19961211
	US 6211245	B1	20010403	US 1998-186341	19981104
	US 6051610	A	20000418	US 1999-252433	19990218
	US 2002004522	A1	20020110	US 2001-825373	20010402
PRAI	US 1993-14813	B2	19930208		
	US 1994-194210	B2	19940208		
	US 1994-288668	B2	19940809		
	WO 1994-US12293	A2	19941026		
	US 1994-288688	A2	19940811		
	EP 1994-932057	A3	19941026		
	US 1995-485038	A	19950607		
	US 1996-663013	A2	19960607		
	WO 1996-US10201	W	19960607		
	US 1996-763480	A2	19961211		

	US 1997-869154	B2	19970604
	US 1997-873011	A1	19970611
	US 1998-186341	A1	19981104

OS MARPAT 133:30571
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CA COPYRIGHT 2003 ACS on STN DUPLICATE 2
AN 132:107773 CA
TI Preparation of aralkylamines as NMDA receptor-ionophore complex antagonists
IN Mueller, Alan L.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Moe, Scott T.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.
PA NPS Pharmaceuticals, Inc., USA
SO U.S., 112 pp., Cont.-in-part of U.S. Ser. No. 663.013.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6017965	A	20000125	US 1996-763480	19961211
	CA 2182680	AA	19950817	CA 1994-2182680	19941026
	WO 9521612	A2	19950817	WO 1994-US12293	19941026
	WO 9521612	A3	19950921		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CN 1148337	A	19970423	CN 1994-195074	19941026
	CN 1088585	B	20020807		
	ES 2156162	T3	20010616	ES 1994-932057	19941026
	EP 1123922	A2	20010816	EP 2000-121960	19941026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	US 6071970	A	20000606	US 1995-485038	19950607
	CA 2257234	AA	19971211	CA 1996-2257234	19961211
	US 6211245	B1	20010403	US 1998-186341	19981104
	US 2002004522	A1	20020110	US 2001-825373	20010402
PRAI	US 1993-14813	B2	19930208		
	US 1994-194210	B2	19940208		
	US 1994-288668	B2	19940809		
	WO 1994-US12293	A2	19941026		
	US 1995-485038	A2	19950607		
	US 1996-663013	A2	19960607		
	US 1994-288688	A2	19940811		
	EP 1994-932057	A3	19941026		
	WO 1996-US19525	A	19961206		
	US 1996-763480	A2	19961211		
	US 1997-869154	B2	19970604		
	US 1997-873011	A1	19970611		
	US 1998-186341	A1	19981104		

OS MARPAT 132:107773
RE.CNT 172 THERE ARE 172 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CA COPYRIGHT 2003 ACS on STN
AN 128:61341 CA
TI Preparation of aralkylamines as NMDA receptor-ionophore complex antagonists
IN Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Vanwagenen,

Bradford C.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.

PA NPS Pharmaceuticals, Inc., USA; Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.

SO PCT Int. Appl., 298 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9746511	A1	19971211	WO 1996-US20697	19961211
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2257234	AA	19971211	CA 1996-2257234	19961211
	AU 9713525	A1	19980105	AU 1997-13525	19961211
	AU 723349	B2	20000824		
	EP 912494	A1	19990506	EP 1996-945069	19961211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511835	T2	20020416	JP 1998-500538	19961211
PRAI	US 1996-663013	A	19960607		
	WO 1996-US19525	A	19961206		
	WO 1996-US20697	W	19961211		

OS MARPAT 128:61341

L5 ANSWER 4 OF 5 CA COPYRIGHT 2003 ACS on STN

AN 126:143970 CA

TI Preparation of 1-amino-3,3-diphenylpropanes and related compounds as noncompetitive antagonists of glutamate receptor operated calcium channels in the central nervous system.

IN Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Delmar, Eric G.; Vanwagenen, Bradford C.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.

PA Nps Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 313 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640097	A1	19961219	WO 1996-US10201	19960607
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6071970	A	20000606	US 1995-485038	19950607
	AU 9661125	A1	19961230	AU 1996-61125	19960607
	AU 716122	B2	20000217		
	EP 831799	A1	19980401	EP 1996-918477	19960607
	EP 831799	B1	20030502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11506469	T2	19990608	JP 1996-502238	19960607
	BR 9609019	A	19990706	BR 1996-9019	19960607
	NZ 310344	A	20010330	NZ 1996-310344	19960607
	AT 238782	E	20030515	AT 1996-918477	19960607
	PL 185492	B1	20030530	PL 1996-323871	19960607

PRAI US 1995-485038 A 19950607
US 1993-14813 B2 19930208
US 1994-194210 B2 19940208
US 1994-288668 B2 19940809
WO 1994-US12293 A2 19941026
WO 1996-US10201 W 19960607
OS MARPAT 126:143970

L5 ANSWER 5 OF 5 USPATFULL on STN
AN 96:72128 USPATFULL
TI Universal, hydraulic, self adjusting, work clamping device
IN Schuit, Johannes, 1433 Camilo Trillado, Carpinteria, CA, United States 93013
PI US 5544872 19960813
AI US 1994-288688 19940811 (8)
DT Utility
FS Granted
LN.CNT 256
INCL INCLM: 269/026.000
INCLS: 269/060.000; 269/148.000; 269/208.000; 269/266.000
NCL NCLM: 269/026.000
NCLS: 269/060.000; 269/148.000; 269/208.000; 269/266.000
IC [6]
ICM: B25B005-14
EXF 269/266; 269/60; 269/91-94; 269/204; 269/208; 269/148; 269/20; 269/25; 269/26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

6 ANSWER 1 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:8522 USPATFULL

TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, UNITED STATES
Moe, Scott T., Salt Lake City, UT, UNITED STATES

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004522	A1	20020110
APPLICATION INFO.:	US 2001-825373	A1	20010402 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-186341, filed on 4 Nov 1998, GRANTED, Pat. No. US 6211245 Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, GRANTED, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995, GRANTED, Pat. No. US 6071970 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994, UNKNOWN Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, GRANTED, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, ABANDONED

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Foley & Lardner, 23rd Floor, 402 W. Broadway, San Diego, CA, 92101-3542

NUMBER OF CLAIMS: 31

EXEMPLARY CLAIM: 1

LINE COUNT: 6312

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2001:185346 USPATFULL

TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6306912 B1 20011023
APPLICATION INFO.: US 1995-483294 19950607 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, now patented, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Celsa, Bennett
ASSISTANT EXAMINER: Hsu, Grace
LEGAL REPRESENTATIVE: Warburg, Richard J.Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:48118 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211245	B1	20010403
APPLICATION INFO.:	US 1998-186341		19981104 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997 Continuation-in-part of Ser. No. US 1997-869154, filed on 4 Jun 1997, now abandoned Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, now patented, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:70898 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071970		20000606
APPLICATION INFO.:	US 1995-485038		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 185
EXEMPLARY CLAIM: 1
LINE COUNT: 5430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:47267 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051610		20000418
APPLICATION INFO.:	US 1999-252433		19990218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:9954 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
Smith, Daryl L., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017965		20000125
APPLICATION INFO.:	US 1996-763480		19961211 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a

continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 6207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 7 CA COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 91:56595 CA
TITLE: Diarylallylamines and diarylpropylamines as **antidepressants**
PATENT ASSIGNEE(S): Astra Lakemedel AB, Swed.
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54039057	A2	19790324	JP 1978-81818	19780704
GB 1602290	A	19811111	GB 1977-27992	19770704
FI 7802093	A	19790105	FI 1978-2093	19780629
FI 64936	B	19831031		
FI 64936	C	19840210		
DK 7802951	A	19790105	DK 1978-2951	19780629
AU 7837612	A1	19800103	AU 1978-37612	19780629
AU 519960	B2	19820107		
CA 1111041	A1	19811020	CA 1978-306650	19780630
NO 7802305	A	19790105	NO 1978-2305	19780703
NO 146743	B	19820823		
NO 146743	C	19821201		
AT 7804835	A	19810115	AT 1978-4835	19780704
AT 363456	B	19810810		
EP 28682	A2	19810520	EP 1980-105028	19800824
EP 28682	A3	19810805		
AT 8004933	A	19820415	AT 1980-4933	19801003
AT 368988	B	19821125		

PRIORITY APPLN. INFO.:

GB 1977-27992	19770704
GB 1978-21249	19780522
EP 1978-850006	19780703
AT 1978-4835	19780704

GI



I



II

AB Diarylallylamines and diarylpropylamines (I, II; R = H, alkyl, alkoxy, halo, CF3, amino; R1 = aryl, pyridyl; R2 = alkyl; R3 = H, alkyl) and their salts were prepd. and were effective **antidepressants** as tested in mice for noradrenaline and 5-hydroxytryptamine absorption with ED50 of 4.1-100 .mu.mol/kg. Thus, 27.5 g 4-(3-bromophenyl)-4-phenyl-2-butanone oxime was reduced with 3.5 g LiAlH4 in THF at room temp. to give 8.9 g crude II (R = 3-Br, R1 = Ph, R2 = Me, R3 = H) (III), which (7.9 g) was treated with 1.1 g oxalic acid in Me2CHOH to give 4.43 pure III.1/2 oxalate. Similarly prepd. were 24 addnl. I and I.

L6 ANSWER 1 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2002:8522 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, UNITED STATES
Moe, Scott T., Salt Lake City, UT, UNITED STATES
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004522	A1	20020110
APPLICATION INFO.:	US 2001-825373	A1	20010402 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-186341, filed on 4 Nov 1998, GRANTED, Pat. No. US 6211245 Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, GRANTED, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995, GRANTED, Pat. No. US 6071970 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994, UNKNOWN Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, GRANTED, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Foley & Lardner, 23rd Floor, 402 W. Broadway, San Diego, CA, 92101-3542
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 6312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:185346 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6306912 B1 20011023
APPLICATION INFO.: US 1995-483294 19950607 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, now patented, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Celsa, Bennett
ASSISTANT EXAMINER: Hsu, Grace
LEGAL REPRESENTATIVE: Warburg, Richard J.Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:48118 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211245	B1	20010403
APPLICATION INFO.:	US 1998-186341		19981104 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997 Continuation-in-part of Ser. No. US 1997-869154, filed on 4 Jun 1997, now abandoned Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, now patented, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:70898 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071970		20000606
APPLICATION INFO.:	US 1995-485038		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 185
EXEMPLARY CLAIM: 1
LINE COUNT: 5430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:47267 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051610		20000418
APPLICATION INFO.:	US 1999-252433		19990218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2000:9954 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
Smith, Daryl L., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017965		20000125
APPLICATION INFO.:	US 1996-763480		19961211 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a

continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 6207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 7 CA COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 91:56595 CA
TITLE: Diarylallylamines and diarylpropylamines as **antidepressants**
PATENT ASSIGNEE(S): Astra Lakemedel AB, Swed.
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54039057	A2	19790324	JP 1978-81818	19780704
GB 1602290	A	19811111	GB 1977-27992	19770704
FI 7802093	A	19790105	FI 1978-2093	19780629
FI 64936	B	19831031		
FI 64936	C	19840210		
DK 7802951	A	19790105	DK 1978-2951	19780629
AU 7837612	A1	19800103	AU 1978-37612	19780629
AU 519960	B2	19820107		
CA 1111041	A1	19811020	CA 1978-306650	19780630
NO 7802305	A	19790105	NO 1978-2305	19780703
NO 146743	B	19820823		
NO 146743	C	19821201		
AT 7804835	A	19810115	AT 1978-4835	19780704
AT 363456	B	19810810		
EP 28682	A2	19810520	EP 1980-105028	19800824
EP 28682	A3	19810805		
AT 8004933	A	19820415	AT 1980-4933	19801003
AT 368988	B	19821125		

PRIORITY APPLN. INFO.:

GB 1977-27992	19770704
GB 1978-21249	19780522
EP 1978-850006	19780703
AT 1978-4835	19780704

GI



I



II

AB Diarylallylamines and diarylpropylamines (I, II; R = H, alkyl, alkoxy, halo, CF3, amino; R1 = aryl, pyridyl; R2 = alkyl; R3 = H, alkyl) and their salts were prepd. and were effective **antidepressants** as tested in mice for noradrenaline and 5-hydroxytryptamine absorption with ED50 of 4.1-100 .mu.mol/kg. Thus, 27.5 g 4-(3-bromophenyl)-4-phenyl-2-butanone oxime was reduced with 3.5 g LiAlH4 in THF at room temp. to give 8.9 g crude II (R = 3-Br, R1 = Ph, R2 = Me, R3 = H) (III), which (7.9 g) was treated with 1.1 g oxalic acid in Me2CHOH to give 4.43 pure III.1/2 oxalate. Similarly prepd. were 24 addnl. I and I.

1 ANSWER 1 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2002:8522 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, UNITED STATES
Moe, Scott T., Salt Lake City, UT, UNITED STATES
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004522	A1	20020110
APPLICATION INFO.:	US 2001-825373	A1	20010402 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-186341, filed on 4 Nov 1998, GRANTED, Pat. No. US 6211245 Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, GRANTED, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995, GRANTED, Pat. No. US 6071970 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994, UNKNOWN Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, GRANTED, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Foley & Lardner, 23rd Floor, 402 W. Broadway, San Diego, CA, 92101-3542
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 6312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2001:185346 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6306912 B1 20011023
APPLICATION INFO.: US 1995-483294 19950607 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, now patented, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Celsa, Bennett
ASSISTANT EXAMINER: Hsu, Grace
LEGAL REPRESENTATIVE: Warburg, Richard J.Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2001:48118 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211245	B1	20010403
APPLICATION INFO.:	US 1998-186341		19981104 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997 Continuation-in-part of Ser. No. US 1997-869154, filed on 4 Jun 1997, now abandoned Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, now patented, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2000:47267 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051610		20000418
APPLICATION INFO.:	US 1999-252433		19990218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

12 7/13/98

L7 ANSWER 1 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2002:8522 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, UNITED STATES
Moe, Scott T., Salt Lake City, UT, UNITED STATES
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004522	A1	20020110
APPLICATION INFO.:	US 2001-825373	A1	20010402 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-186341, filed on 4 Nov 1998, GRANTED, Pat. No. US 6211245 Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, GRANTED, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995, GRANTED, Pat. No. US 6071970 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994, UNKNOWN Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, GRANTED, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Foley & Lardner, 23rd Floor, 402 W. Broadway, San Diego, CA, 92101-3542
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 6312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2001:185346 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
VanWagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6306912 B1 20011023
APPLICATION INFO.: US 1995-483294 19950607 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288688, filed on 11 Aug 1994, now patented, Pat. No. US 5544872 Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Celsa, Bennett
ASSISTANT EXAMINER: Hsu, Grace
LEGAL REPRESENTATIVE: Warburg, Richard J.Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2001:48118 USPATFULL
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211245	B1	20010403
APPLICATION INFO.:	US 1998-186341		19981104 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-873011, filed on 11 Jun 1997 Continuation-in-part of Ser. No. US 1997-869154, filed on 4 Jun 1997, now abandoned Continuation-in-part of Ser. No. US 1996-763480, filed on 11 Dec 1996, now patented, Pat. No. US 6017965 Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 Continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 Continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 36 CA COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 133:30571 CA
TITLE: Preparation of aralkylamines active at receptor-operated calcium channels as neuroprotectants
INVENTOR(S): Mueller, Alan L.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Moe, Scott T.; Artman, Linda D.; Barmore, Robert M.
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
SOURCE: U.S., 133 pp., Cont.-in-part of WO 9511663.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6071970	A	20000606	US 1995-485038	19950607
CA 2182680	AA	19950817	CA 1994-2182680	19941026
WO 9521612	A2	19950817	WO 1994-US12293	19941026
WO 9521612	A3	19950921		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1148337	A	19970423	CN 1994-195074	19941026
CN 1088585	B	20020807		
ES 2156162	T3	20010616	ES 1994-932057	19941026
EP 1123922	A2	20010816	EP 2000-121960	19941026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CA 2223978	AA	19961219	CA 1996-2223978	19960607
WO 9640097	A1	19961219	WO 1996-US10201	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9661125	A1	19961230	AU 1996-61125	19960607
AU 716122	B2	20000217		
EP 831799	A1	19980401	EP 1996-918477	19960607
EP 831799	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1192679	A	19980909	CN 1996-196042	19960607
JP 11506469	T2	19990608	JP 1996-502238	19960607

BR 9609019	A	19990706	BR 1996-9019		19960607
NZ 310344	A	20010330	NZ 1996-310344		19960607
AT 238782	E	20030515	AT 1996-918477		19960607
PL 185492	B1	20030530	PL 1996-323871		19960607
US 6017965	A	20000125	US 1996-763480		19961211
US 6211245	B1	20010403	US 1998-186341		19981104
US 6051610	A	20000418	US 1999-252433		19990218
US 2002004522	A1	20020110	US 2001-825373		20010402

PRIORITY APPLN. INFO.:

US 1993-14813	B2	19930208
US 1994-194210	B2	19940208
US 1994-288668	B2	19940809
WO 1994-US12293	A2	19941026
US 1994-288688	A2	19940811
EP 1994-932057	A3	19941026
US 1995-485038	A	19950607
US 1996-663013	A2	19960607
WO 1996-US10201	W	19960607
US 1996-763480	A2	19961211
US 1997-869154	B2	19970604
US 1997-873011	A1	19970611
US 1998-186341	A1	19981104

OTHER SOURCE(S): MARPAT 133:30571

AB Title compds., e.g., RCHR4CR1R5CR2R6R7 [R = (un)substituted Ph; R1,R5 = H, OH, (hydroxy)alkyl, alkoxy, acyloxy; R2,R6 = H or hydroxyalkyl; R1R2 = (CH2)n or (CH2)nNR3; R3 = H, alkyl, CH2CH2OH; R4 = (cyclo)alkyl, or (un)substituted Ph; R7 = N(R3)2; R7 = H when R1R2 = (CH2)nNR3; n = 1-6] were prepd. Thus, (4-FC6H4)2CO was condensed with (EtO)2P(O)CH2CN and the product converted in 2 redn. steps to (4-FC6H4)2CHCH2CH2NH2. Data for biol. activity of title compds. were given.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 36 CA COPYRIGHT 2003 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 132:107773 CA

TITLE: Preparation of aralkylamines as NMDA receptor-ionophore complex antagonists

INVENTOR(S): Mueller, Alan L.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Moe, Scott T.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA

SOURCE: U.S., 112 pp., Cont.-in-part of U.S. Ser. No. 663.013.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6017965	A	20000125	US 1996-763480	19961211
CA 2182680	AA	19950817	CA 1994-2182680	19941026
WO 9521612	A2	19950817	WO 1994-US12293	19941026
WO 9521612	A3	19950921		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1148337	A	19970423	CN 1994-195074	19941026
CN 1088585	B	20020807		
ES 2156162	T3	20010616	ES 1994-932057	19941026
EP 1123922	A2	20010816	EP 2000-121960	19941026

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

US 6071970	A	20000606	US 1995-485038	19950607
CA 2257234	AA	19971211	CA 1996-2257234	19961211
US 6211245	B1	20010403	US 1998-186341	19981104
US 2002004522	A1	20020110	US 2001-825373	20010402

PRIORITY APPLN. INFO.:

US 1993-14813	B2	19930208
US 1994-194210	B2	19940208
US 1994-288668	B2	19940809
WO 1994-US12293	A2	19941026
US 1995-485038	A2	19950607
US 1996-663013	A2	19960607
US 1994-288688	A2	19940811
EP 1994-932057	A3	19941026
WO 1996-US19525	A	19961206
US 1996-763480	A2	19961211
US 1997-869154	B2	19970604
US 1997-873011	A1	19970611
US 1998-186341	A1	19981104

OTHER SOURCE(S): MARPAT 132:107773

AB R7CHR4CR1R5CRR2R6[I; R = H or N(R3)2; R1,R5 = (un)substituted Ph, -CH2Ph, -OPh; R2,R6 = H or (hydroxy)alkyl; R1R2 = (CH2)n or (CH2)nNR3(CH2)n; R2R6 = NH; R3 = H, alkyl, CH2CH2OH, alkylphenyl; R4 = (un)substituted Ph, -pyridyl, -thienyl, etc.; R7 = (un)substituted Ph; n = 0-6] were prepd. Thus, (3-FC6H4)2CO was condensed with (EtO)2P(O)CH2CO2Et and the product converted in 6 steps to (3-FC6H4)2CHCH2CHMeNH2. Data for biol. activity of I were given.

REFERENCE COUNT: 172 THERE ARE 172 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2000:47267 USPATFULL

TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
Artman, Linda D., Salt Lake City, UT, United States
Barmore, Robert M., Salt Lake City, UT, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051610		20000418
APPLICATION INFO.:	US 1999-252433		19990218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1
LINE COUNT: 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 134:85983 CA
TITLE: Chiral synthesis and pharmacological evaluation of NPS 1407: a potent, stereoselective NMDA receptor antagonist
AUTHOR(S): Moe, Scott T.; Smith, Daryl L.; DelMar, Eric G.; Shimizu, Scot M.; Van Wagenen, Bradford C.; Balandrin, Manuel F.; Chien, Yongwei; Raszkiewicz, Joanna L.; Artman, Linda D.; White, H. Steve; Mueller, Alan L.
CORPORATE SOURCE: Medicinal Chemistry Pharmacology Groups, NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(21), 2411-2415
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:85983
GI



I

AB The stereoselective synthesis and biol. activity of NPS 1407 (I), a potent, stereoselective antagonist of the NMDA receptor, was described. (.+-.)-I was found to be active at the NMDA receptor in an in vitro assay, prompting the synthesis of the individual stereoisomers. I was found to be 12 times more potent than its R enantiomer and demonstrated in vivo pharmacol. activity in neuroprotection and anticonvulsant assays.
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 132:44496 CA
TITLE: Improved alignment by weighted field fit in CoMFA of histamine H2 receptor agonistic imidazolylpropylguanidines
AUTHOR(S): Dove, Stefan; Buschauer, Armin
CORPORATE SOURCE: Institute of Pharmacy, University Regensburg, Regensburg, D-93040, Germany
SOURCE: Quantitative Structure-Activity Relationships (1999), 18(4), 329-341
CODEN: QSARDI; ISSN: 0931-8771

PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB More realistic description of ligand-receptor interactions in CoMFA results from alignments considering surface and field properties instead of only mol. frameworks. The field fit algorithm implemented in SYBYL (Tripos Ass.) as part of the energy minimizer provides the possibility to assign individual wts. to grid points. A new weighting function derives the significance of grid points for the alignment of fields from preceding CoMFA runs, using regression coeffs., means, and std. deviations of field variables as parameters. Just in strongly diverse congeneric series, the method does not underestimate the common structure and not overweight variable, interacting regions. CoMFA of a large series of 142 histamine H2 receptor agonistic imidazolylpropylguanidines (pD2 values from guinea pig atrium) is presented as example. Results with three different alignments were compared: (1) exact superposition of the const. imidazolylpropylguanidine moiety, (2) SUPERIMPOSE or FIT of energy min., (3) minimization of the structures by weighted field fit with wts. based on CoMFA with alignment 2. A significant improvement of cross-validated PLS results was obsd. from alignment to alignment: Leave-one-out approach: (1) 7 PC's, Q2=0.59, sPRESS=0.50, (2) 8 PC's, Q2=0.66, sPRESS=0.46, (3) 9 PC's, Q2=0.71, sPRESS=0.42. Cross validation with 10 groups (mean of 10 runs): (1) 6.3 PC's, Q2=0.59, sPRESS=0.50, (2) 6.1 PC's, Q2=0.65, sPRESS=0.47, (3) 9.5 PC's, Q2=0.71, sPRESS=0.43. It is concluded that risks of the field fit method like producing artificial redundancy of the structures and ignoring entropy contributions to the free energy of binding are lowered with the given weighting method.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 36 CA
ACCESSION NUMBER: 130:66268 CA
TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
INVENTOR(S): Mueller, Alan L.; Moe, Scott T.
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856752	A1	19981217	WO 1998-US11608	19980611
W: JP				

PRIORITY APPLN. INFO.: US 1997-873011 A 19970611
OTHER SOURCE(S): MARPAT 130:66268
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The compds. [I, II, III; R1 and R3 are independently selected from (un)substituted Ph, benzyl, phenoxy, H, alkyl, OH, etc.; R2 and R5 are independently selected from H, alkyl, hydroxyalkyl; R2-R5 together are imino; R1-R2 together are (CH2)n, (CH2)n-N(R6)-(CH2)n; n = 0-6, at least one n greater than 0; R6 is H, alkyl, 2-hydroxyethyl, and alkylphenyl; R4 is selected from (un)substituted thiofuryl, pyridyl, Ph, benzyl, phenoxy, phenylthio, H, alkyl, chcloalkyl; X, X1 is independently selected from

(un)substituted Ph, benzyl, phenoxy, F, Cl, Br, Oh, etc.; m = 0-5; Y is N(R6)2, H when R1-R2 together are (CH2)n-N(R6)-(CH2)n], pharmaceutical compns., and pharmaceutical acceptable salts, complexes, and carriers are prepd. as antagonists of NMDA receptor-mediated responses for treating a neurol. disease or disorder such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 36 CA COPYRIGHT 2003 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 129:156780 CA

TITLE: Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats

AUTHOR(S): Gurevich, Boris; Artru, Alan A.; Lam, Arthur M.; Mueller, Alan L.; Merkind, Vladimir; Talmor, Daniel; Katchko, Ludmila; Shapira, Yoram

CORPORATE SOURCE: Department of Anesthesiology, Kaplan Hospital, Rehovot, Israel

SOURCE: Journal of Neurosurgery (1998), 88(6), 1066-1074
CODEN: JONSAC; ISSN: 0022-3085

PUBLISHER: American Association of Neurological Surgeons

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors sought to det. whether 3,3-bis(3-fluorophenyl)propylamine (NPS 846), a novel noncompetitive N-methyl-D-aspartate receptor antagonist, alters outcome after closed head trauma in rats. The exptl. variables were: presence or absence of closed head trauma, treatment with NPS 846 or no treatment, and time at which the rats were killed (24 or 48 h). The NPS 846 (1 mg/kg) was administered i.p. at 1 and 3 h after closed head trauma or sham operation. Outcome measures were the neurol. severity score (NSS), ischemic tissue vol., hemorrhagic necrosis vol., and sp. gr., water content, and concns. of calcium, sodium, potassium, and magnesium in brain tissue. The following closed head trauma-induced changes in the injured hemisphere (expressed as the mean .+-. the std. deviation) were reversed by NPS 846: decreased sp. gr. of 1.035 .+-. 0.006 at 24 h was increased to 1.042 .+-. 0.004; the decreased potassium level of 0.583 .+-. 0.231 mg/L at 48 h and at 24 h was increased to 2.442 .+-. 0.860 mg/L; the increased water content of 84.7 .+-. 2.6% at 24 h was decreased to 79.8 .+-. 2%; the increased calcium level of 0.592 .+-. 0.210 mg/L at 24 h was decreased to 0.048 .+-. 0.029 mg/L; and the increased sodium level of 2.035 .+-. 0.649 mg/L was decreased to 0.631 .+-. 0.102 mg/L. Administration of NPS 846 also lowered the NSS (improved neurol. status) at 48 h (7 .+-. 3) and caused no significant changes in ischemic tissue or hemorrhagic necrosis vols. in the injured hemisphere at 24 or 48 h. In this model of closed head trauma, NPS 846 improved neurol. outcome, delayed the onset of brain edema, and improved brain tissue ion homeostasis.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 36 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 129:156415 CA

TITLE: Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs

AUTHOR(S): Andersson, Stig H. G.; Lindgren, Anders; Postlind, Hans

CORPORATE SOURCE: Department of Drug Metabolism, Pharmacia & Upjohn AB, Uppsala, S-751 82, Swed.

SOURCE: Drug Metabolism and Disposition (1998), 26(6), 528-535
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tolterodine is intended for the treatment of urinary urge incontinence and other symptoms assocd. with an overactive bladder. The in vivo metab. of 14C-labeled tolterodine was investigated in rats, mice, and dogs by anal. of blood and urine samples, whereas in vitro metab. studies were performed by incubation of [14C]tolterodine with mouse, rat, dog, and human liver microsomes in the presence of NADPH. Tolterodine was extensively metabolized in vivo. Mice and dogs showed similar metabolite patterns, which correlated well with that obsd. in humans. In these species, tolterodine was metabolized along 2 different pathways, with the more important being the stepwise oxidn. of the 5-Me group to yield the 5-hydroxymethyl metabolite of tolterodine and then, via the aldehyde, the 5-carboxylic acid metabolite. The other pathway involved dealkylation of the nitrogen. In the subsequent phase II metab., tolterodine and the metabolites were conjugated with glucuronic acid to various degrees. Rats had a more extensive metab. and a markedly different metabolite pattern, with metabolites also being formed by hydroxylation of the nonsubstituted benzene ring. Gender differences were also obsd., with male rats showing more extensive metab. than females. Incubation of [14C]tolterodine yielded 5 metabolites with rat microsomes and 3 metabolites with mouse, dog, and human microsomes. The 5-hydroxymethyl metabolite of tolterodine and N-dealkylated tolterodine were major metabolites in all incubations, representing 83-99% of total metab. Although the extent of metab. varied among the species, the metabolic profiles were similar. Rat liver microsomes also formed metabolites hydroxylated in the nonsubstituted benzene ring. Thus, the metab. of tolterodine in mice and dogs corresponds to that obsd. in humans, whereas rats have a different metabolite pattern.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 129:197557 CA
TITLE: Imidazolylpropylguanidines as histamine H2 receptor agonists: 3D-QSAR of a large series
AUTHOR(S): Dove, Stefan; Buschauer, Armin
CORPORATE SOURCE: Institute of Pharmacy, University Regensburg, Regensburg, D-93040, Germany
SOURCE: Pharmaceutica Acta Helvetiae (1998), 73(3), 145-155
CODEN: PAHEAA; ISSN: 0031-6865
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Imidazolylpropylguanidines are potent histamine H2 receptor agonists and act as inotropic vasodilators. A large series of 141 derivs. was tested in the isolated guinea pig atrium and submitted to CoMFA. Since all compds. are full agonists, pD2 values reflect H2 receptor binding. Hydrophobicity was considered as .SIGMA.f of the variable structural moiety, calcd. by the Leo-Hansch method. Preliminary Hansch anal. with .SIGMA.f, (.SIGMA.f)2 and indicator variables showed that pD2 additively depends on contributions of certain substructures and has a hydrophobic optimum. For CoMFA, all 3D structures were optimized and aligned. Partial Least Squares anal. of pD2 as function of steric and electrostatic field variables and of .SIGMA.f and (.SIGMA.f)2 led to models with r2 of 0.78 with and 0.93 without hydrophobicity. Results indicate a parabolic dependence of pD2 on hydrophobic effects. The 3D distribution of field influences on pD2 suggests a model (shape and electrostatic potential) of the binding site. The role of branching and different substituent effects of a first and a second ring indicate that adequately branched structures induce a conformational change of the binding site enabling a favorable

accommodation of the second ring with various substituents.
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 128:61341 CA
TITLE: Preparation of aralkylamines as NMDA receptor-ionophore complex antagonists
INVENTOR(S): Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA; Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.
SOURCE: PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746511	A1	19971211	WO 1996-US20697	19961211
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2257234	AA	19971211	CA 1996-2257234	19961211
AU 9713525	A1	19980105	AU 1997-13525	19961211
AU 723349	B2	20000824		
EP 912494	A1	19990506	EP 1996-945069	19961211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511835	T2	20020416	JP 1998-500538	19961211

PRIORITY APPLN. INFO.: US 1996-663013 A 19960607
WO 1996-US19525 A 19961206
WO 1996-US20697 W 19961211
OTHER SOURCE(S): MARPAT 128:61341
AB R7CHR4CR1R5CRR2R6 [I; R = H or N(R3)2; R1,R5 = (un)substituted Ph, -CH2Ph, -OPh; R2,R6 = H or (hydroxy)alkyl; R1R2 = (CH2)n or (CH2)nNR3(CH2)n; R2R6 = NH; R3 = H, alkyl, CH2CH2OH, alkylphenyl; R4 = (un)substituted Ph, -pyridyl, -thienyl, etc.; R7 = (un)substituted Ph; n = 0-6] were prepd. Thus, (3-FC6H4)2CO was condensed with (EtO)2P(O)CH2CO2Et and the product converted in 6 steps to (3-FC6H4)2CHCH2CHMeNH2. Data for biol. activity of I were given.

L7 ANSWER 14 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 127:44446 CA
TITLE: Stepwise leave-one-isomer-out free-Wilson approaches as preprocessing tools in QSAR analysis of racemates
AUTHOR(S): Dove, Stefan; Buschauer, Armin
CORPORATE SOURCE: Institute of Pharmacy, University Regensburg, Regensburg, D-93040, Germany
SOURCE: Quantitative Structure-Activity Relationships (1997), 16(1), 11-19
CODEN: QSARDI; ISSN: 0931-8771
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB QSAR anal. of racemates is complicated if specific substituent-receptor interactions and, by that, specific spatial fits to the binding site

result in individual but unknown activity differences of enantiomers, and even in structure-dependent changes of which is the more active configuration. In a first approxn., additivity of substituent contributions should be assumed instead of major conformational effects. Then, Free-Wilson anal. (FWA) can be used as preprocessing tool to reduce a starting set of all pairs of enantiomers into a final series of the probably (more) active configurations. A stepwise "leave-one-isomer-out" approach is applied, where the model is successively improved by checking all remaining pairs and leaving out one enantiomer, detd. by a special criterion of poorest prediction, in each step. The final model is given by the maximal F value. This approach was applied to histamine H1 antagonistic activity (pKB, guinea pig ileum) of 19 racemic and six non-chiral phenyl-halogenated N-(diphenylpropyl)-N'-(imidazolylpropyl)guanidines. Based on only eight variables because of additivity of meta and para contributions, the starting model with n = 44, r2 = 0.29, s = 0.52, F = 1.8, r2-PRESS=-0.14 has been improved to a final one with n = 31 (only six remaining pairs), r2 = 0.84, s = 0.24, F = 14.0, r2-PRESS=0.65. Addnl., each of the successive series was submitted to CoMFA. Statistical parameters of the parallel CoMFA and FWA models are closely related. QSAR results obtained with both methods correspond to well-known structure-activity relationships of diphenhydramine-like H1 antagonists. A direct application of the leave-one-isomer-out strategy to CoMFA was less successful.

L7 ANSWER 15 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 126:143970 CA
TITLE: Preparation of 1-amino-3,3-diphenylpropanes and related compounds as noncompetitive antagonists of glutamate receptor operated calcium channels in the central nervous system.
INVENTOR(S): Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Delmar, Eric G.; Vanwagenen, Bradford C.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.
PATENT ASSIGNEE(S): Nps Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640097	A1	19961219	WO 1996-US10201	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6071970	A	20000606	US 1995-485038	19950607
AU 9661125	A1	19961230	AU 1996-61125	19960607
AU 716122	B2	20000217		
EP 831799	A1	19980401	EP 1996-918477	19960607
EP 831799	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11506469	T2	19990608	JP 1996-502238	19960607
BR 9609019	A	19990706	BR 1996-9019	19960607
NZ 310344	A	20010330	NZ 1996-310344	19960607
AT 238782	E	20030515	AT 1996-918477	19960607
PL 185492	B1	20030530	PL 1996-323871	19960607

PRIORITY APPLN. INFO.: US 1995-485038 A 19950607
US 1993-14813 B2 19930208
US 1994-194210 B2 19940208

US 1994-288668 B2 19940809
WO 1994-US12293 A2 19941026
WO 1996-US10201 W 19960607

OTHER SOURCE(S): MARPAT 126:143970

GI



I

AB Title compds. [I; R1, R5 = H, OH, alkyl, hydroxyalkyl, alkoxy, acyloxy, (substituted) Ph, PhCH2, PhO; R2, R6 = H, alkyl, hydroxyalkyl; R2R4 = imino, (CH2)n, (CH2)nNR3(CH2)n; R3 = H, alkyl, HOCH2CH2, alkylphenyl; n = 0-6, only 1 n can = 0; R4 = (substituted) thiofuryl, pyridyl, Ph, PhCH2, PhO, PhS; X = (substituted) Ph, PhCH2, PhO; m = 0-5; Y = N(R3)2; when R1R2 = (CH2)nNR3(CH2)n, then Y = H], were prepd. Thus, di-Et cyanomethylphosphonate was stirred 4 h with NaH in dimethoxyethane; 3,3'-difluorobenzophenone in dimethoxyethane was added and the mixt. was stirred 24 h at room temp. to give the cyanomethyl carbinol, which was hydrogenated to give an aminopropanol which was dehydrated and hydrogenated to give 3,3-bis(3-fluorophenyl)propylamine hydrochloride. The latter showed anticonvulsant activity against electroshock-induced seizures in mice with ED50 = 20.1 mg/kg i.p.

L7 ANSWER 16 OF 36 USPATFULL on STN

ACCESSION NUMBER: 96:72128 USPATFULL

TITLE: Universal, hydraulic, self adjusting, work clamping device

INVENTOR(S): Schuit, Johannes, 1433 Camilo Trillado, Carpinteria, CA, United States 93013

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5544872		19960813	
APPLICATION INFO.:	US 1994-288688		19940811	(8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Watson, Robert C.

LEGAL REPRESENTATIVE: Haefliger, William W.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Apparatus for clamping and orienting work relative to a tool, for processing, comprising, in combination two laterally extending longitudinally separated support bars, and connector means connected to and extending between the bars for positioning them in fixed separated condition, there being work receiving space between the bars; bar leveling means extending downwardly from the bars for supporting the bars on a support bed, the means being adjustable to adjust the leveling of the bars; and work clamping pistons carried by the bars for hydraulically actuated movement toward the work receiving space for engaging and clamping the work to hold the work in fixed position relative to the bed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 36 CA COPYRIGHT 2003 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 123:306618 CA
TITLE: Arylalkylamine compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases, and preparation of these compounds
INVENTOR(S): Mueller, Alan L.; Van Wagenen, Bradford C.; Delmar, Eric G.; Balandrin, Manuel F.; Moe, Scott T.; Artman, Linda D.
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9521612	A2	19950817	WO 1994-US12293	19941026
WO 9521612	A3	19950921		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2182680	AA	19950817	CA 1994-2182680	19941026
AU 9480923	A1	19950829	AU 1994-80923	19941026
AU 710575	B2	19990923		
EP 743853	A1	19961127	EP 1994-932057	19941026
EP 743853	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1148337	A	19970423	CN 1994-195074	19941026
CN 1088585	B	20020807		
JP 09509484	T2	19970922	JP 1994-521191	19941026
AT 200862	E	20010515	AT 1994-932057	19941026
ES 2156162	T3	20010616	ES 1994-932057	19941026
EP 1123922	A2	20010816	EP 2000-121960	19941026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
RU 2201224	C2	20030327	RU 1996-118132	19941026
US 6071970	A	20000606	US 1995-485038	19950607
US 6306912	B1	20011023	US 1995-483294	19950607
US 6017965	A	20000125	US 1996-763480	19961211
US 6211245	B1	20010403	US 1998-186341	19981104
US 6051610	A	20000418	US 1999-252433	19990218
US 2002004522	A1	20020110	US 2001-825373	20010402

PRIORITY APPLN. INFO.:
US 1993-14813 A2 19930208
US 1994-194210 A 19940208
US 1994-288668 A 19940809
US 1994-288688 A2 19940811
EP 1994-932057 A3 19941026
WO 1994-US12293 W 19941026
US 1995-485038 A2 19950607
US 1996-663013 A2 19960607
US 1996-763480 A2 19961211
US 1997-869154 B2 19970604
US 1997-873011 A1 19970611
US 1998-186341 A1 19981104

OTHER SOURCE(S): MARPAT 123:306618
GI



I



II



III

AB A method is provided for identifying a compd. useful for the therapeutic treatment of a neurol. disease or disorder, e.g. stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compds. are active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compd. which binds to the receptor-operated calcium channel at the site bound by arylalkylamine I, II, or III. Prepn. of arylalkylamine compds. and biol. testing are included.

L7 ANSWER 18 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 118:147506 CA
TITLE: Synthesis and histamine H2 agonistic activity of arpromidine analogs: replacement of the pheniramine-like moiety by non-heterocyclic groups.
AUTHOR(S): Buschauer, A.; Friese-Kimmel, A.; Baumann, G.; Schunack, W.
CORPORATE SOURCE: Inst. Pharm., Freie Univ. Berlin, Berlin, W-1000/33, Germany
SOURCE: European Journal of Medicinal Chemistry (1992), 27(4), 321-30
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 118:147506
GI



I

AB Analogs of the potent histamine H2 agonist arpromidine (I), characterized by nonheterocyclic groups (Ph, cyclohexyl, alkyl) instead of the pheniramine-like portion, were prepd. and tested for their H2 agonistic and H1 antagonistic activity in the isolated guinea pig right atrium and ileum, resp. In the diphenylpropylguanidine series, an increase in H2 agonistic potency resulted from mono- or difluorination at one or both Ph rings in the meta and/or para position (pD2 .ltoreq. 7.75 vs pD2 = 7.15 for the unsubstituted parent compd.). Compds. chlorinated at both Ph rings were considerably less potent. Highest combined H2 agonistic/H1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analog with cyclohexyl and Me group instead of Ph and pyridine ring was 30 times more potent than histamine in the atrium. The H1 antagonistic potency in cyclohexyl compds. was lower than in the diaryl series. Thus, arom. rings appear not to be required for high H2 agonistic potency but are useful for combined H2 agonistic/H1 antagonistic activity.

L7 ANSWER 19 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 115:8210 CA
TITLE: Derivatives of arylalkylamines. XXVII. Synthesis and pharmacological activity of several derivs. of [3-(2-hydroxy-5-carboxy)phenyl]-3-phenylpropionic acid
AUTHOR(S): Asoyan, E. L.; Balayan, R. S.; Pogosyan, A. V.; Asatryan, T. O.; Markaryan, E. A.
CORPORATE SOURCE: Inst. Tonk. Org. Khim., Yerevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1990), 43(11), 719-23
CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 115:8210
GI



I

AB The reaction of p-HOC6H4CO2Me with PhCH:CHCO2Me in the presence of AlLCl3 gives ester I. I can be converted to amides II (R = alkyl; X = O) and these in turn reduced to amines II [X = H2 (III)]. The effect of III on the .alpha.-adrenoreceptors and the transmission of impulses by postganglio- sympathetic nerves and antispasmodic activity was studied.

L7 ANSWER 20 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 110:107540 CA
TITLE: Biotransformation of terodiline. IV. Identification of unconjugated and conjugated metabolites in dog and human urine
AUTHOR(S): Noren, Bengt; Stroemberg, Signhild; Ericsson, Oerjan; Lindeke, Bjoern
CORPORATE SOURCE: Kabi AB, Stockholm, S-112 87, Swed.
SOURCE: Acta Pharmaceutica Suecica (1988), 25(6), 281-92
CODEN: APSXAS; ISSN: 0001-6675
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Terodiline is mainly excreted in the form of metabolites. Unconjugated and conjugated metabolites excreted in dog and human urine were identified by mass spectrometry. The major metabolites found in both dog and human urine were N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butanamine, N-tert-butyl-4-(4-hydroxy-3-methoxyphenyl)-4-phenyl-2-butanamine and N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butanamine. Six identified metabolites were excreted mainly as Me and glucuronic acid conjugates.

L7 ANSWER 21 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 100:102836 CA
TITLE: Arylalkylamine derivatives. XIX. Synthesis of some 3-(2-hydroxy-3-methoxyphenyl)-3-phenyl-N-(arylalkyl)propylamines and their biological activity
AUTHOR(S): Balayan, R. S.; Akopyan, M. G.; Kaltrikyan, A. A.; Markaryan, E. A.
CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1983), 36(10), 653-7
CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 100:102836
GI



I

AB PhCH:CHCO2Me reacted with guaiacol in PhNO2 contg. AlCl3 at 80.degree. to give 51.4% dihydrocoumarin I via cyclization of the intermediate 2,3-HO(MeO)C6H3CHPhCH2COX (II; X = OMe). Sapong. I gave 85.4% II (X = OH), which reacted with SOCl2 to give II (X = Cl) and then with RNH2 [R = PhCH2CHMe, 3,4-(MeO)2C6H3, Ph2CHCH2CH2, Ph2CHCH2CHMe, PhCH2CH2CHMe] to give the corresponding II (X = NHR) in 72-92% yield. Reducing the latter with LiAlH4 gave 50-65% 2,3-HO(MeO)C6H3CHPhCH2CH2NHR (same R), which have pronounced and long-term .alpha.-sympatholytic activity (no data).

L7 ANSWER 22 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 100:34210 CA
TITLE: Arylalkylamine derivatives. XVIII. Synthesis and pharmacological activity of some 3-[2-hydroxy-4(or 5)-methylphenyl]-3-phenyl-N-(arylalkyl)propylamines
AUTHOR(S): Balayan, R. S.; Akopyan, M. G.; Kaltrikyan, A. A.; Avakyan, O. M.; Markaryan, E. A.
CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1983), 36(7), 451-6

CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 100:34210
AB Arylation of PhCH:CHCO2Me with p- and m-cresol in the presence of AlCl3 gave 59.4% 6- and 53.4% 7-methyl-4-phenyl-3,4-dihydrocoumarin, resp., which were sapond. with NaOH to give 83.7% 5,2- and 77.5% 4,2-Me(HO)C6H3CHPhCH2CO2H. Treating these with SOCl2 and then RNH2 [R = PhCH2CHMe, 3,4-(MeO)2C6H3CH2CH2, PhCH2CH2CHMe, Ph2CHCH2CH2, Ph2CHCH2CHMe] in refluxing abs. C6H6 gave the corresponding Me(HO)C6H3CHPhCH2CONHR (I), which were also formed in 60-91% yield directly from the dihydrocoumarins and RNH2 in refluxing C6H6. LiAlH4 redn. of I in abs. Et2O gave, after acidification, 49-86% 5,2- and 4,2-Me(HO)C6H3CHPhCH2CH2NHR.cntdot.HCl, which showed significant .alpha.-adrenoblocking activity.

L7 ANSWER 23 OF 36 USPATFULL on STN
ACCESSION NUMBER: 80:52502 USPATFULL
TITLE: Glycerol phosphites esterified with phenolcarboxylic acids
INVENTOR(S): Mayer, Norbert, Gablingen, Germany, Federal Republic of
Pfahler, Gerhard, Augsburg, Germany, Federal Republic of
Scheidl, Franz, Gersthofen, Germany, Federal Republic of
Wiezer, Hartmut, Gersthofen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4229382		19801021
APPLICATION INFO.:	US 1979-19785		19790312 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1978-2811667	19780317

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sutto, Anton H.
LEGAL REPRESENTATIVE: Connolly and Hutz
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel esters of glycerol, in which one of the OH groups of the glycerol is esterified with a phenolcarboxylic acid, while the two other OH groups are esterified with phosphoric or phosphorous acid, substituted by long-chain alcohols, amines, mercaptans or phenol compounds. The products are suitable as light and heat stabilizers for plastics. They are distinguished by a high resistance to hydrolysis and extraction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 91:56595 CA
TITLE: Diarylallylamines and diarylpropylamines as antidepressants
PATENT ASSIGNEE(S): Astra Lakemedel AB, Swed.
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54039057	A2	19790324	JP 1978-81818	19780704
GB 1602290	A	19811111	GB 1977-27992	19770704
FI 7802093	A	19790105	FI 1978-2093	19780629
FI 64936	B	19831031		
FI 64936	C	19840210		
DK 7802951	A	19790105	DK 1978-2951	19780629
AU 7837612	A1	19800103	AU 1978-37612	19780629
AU 519960	B2	19820107		
CA 1111041	A1	19811020	CA 1978-306650	19780630
NO 7802305	A	19790105	NO 1978-2305	19780703
NO 146743	B	19820823		
NO 146743	C	19821201		
AT 7804835	A	19810115	AT 1978-4835	19780704
AT 363456	B	19810810		
EP 28682	A2	19810520	EP 1980-105028	19800824
EP 28682	A3	19810805		
AT 8004933	A	19820415	AT 1980-4933	19801003
AT 368988	B	19821125		

PRIORITY APPLN. INFO.:

GB 1977-27992	19770704
GB 1978-21249	19780522
EP 1978-850006	19780703
AT 1978-4835	19780704

GI



I



II

AB Diarylallylamines and diarylpropylamines (I, II; R = H, alkyl, alkoxy, halo, CF3, amino; R1 = aryl, pyridyl; R2 = alkyl; R3 = H, alkyl) and their salts were prepd. and were effective antidepressants as tested in mice for noradrenaline and 5-hydroxytryptamine absorption with ED50 of 4.1-100 .mu.mol/kg. Thus, 27.5 g 4-(3-bromophenyl)-4-phenyl-2-butanone oxime was reduced with 3.5 g LiAlH4 in THF at room temp. to give 8.9 g crude II (R = 3-Br, R1 = Ph, R2 = Me, R3 = H) (III), which (7.9 g) was treated with 1.1 g oxalic acid in Me2CHOH to give 4.43 pure III.1/2 oxalate. Similarly prepd. were 24 addnl. I and I.

L7 ANSWER 25 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 92:41592 CA
TITLE: Glycerol phosphites esterified with phenolcarboxylic acids
INVENTOR(S): Mayer, Norbert; Pfahler, Gerhard; Scheidl, Franz; Wiezer, Hartmut
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 34 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2811667	A1	19790920	DE 1978-2811667	19780317

EP 4331	A3	19791017	EP 1979-100731	19790312
EP 4331	B1	19810513		
R: BE, CH, DE, FR, GB, NL				
US 4229382	A	19801021	US 1979-19785	19790312
ZA 7901239	A	19800430	ZA 1979-1239	19790316

PRIORITY APPLN. INFO.: DE 1978-2811667 19780317

GI



II



III

AB A series of 30 title compds. was prepd. as stabilizers for thermoplastic homo- and copolymers. Thus, 0.2 mol 4,3,5-HO(Me3C)2C6H2CO2H, 0.26 mol oxiranemethanol (I), 0.1 g KOH, and 0.2 mol 1,2-triacontanediol (reaction medium only at this stage) were stirred 2 h at 110.degree. under N, unreacted I was stripped in vacuo, 0.105 mol (EtO)3PO was added, and the mixt. was distd. to 180.degree. to give 130 g II. Also prepd. was, e.g., III.

L7 ANSWER 26 OF 36 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	85:20811 CA
TITLE:	3,3-Diphenylpropylamine derivatives
INVENTOR(S):	Tokuyama, Kanji; Tanaka, Mamoru
PATENT ASSIGNEE(S):	Shionogi and Co., Ltd., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 5 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50140431	A2	19751111	JP 1974-44765	19740419

PRIORITY APPLN. INFO.: JP 1974-44765 19740419

AB Methoxybenzenes (MeO)nC6H6-n (n = 2,3) were treated with

MeOCH2CH(CN)CH(OMe)2 (I) in the presence of an acid to give [(MeO)nC6H5-n]2CHCH(CH2OMe)CN (II), which were reduced to [(MeO)nC6H5-n]2CHCH(CH2OMe)CH2NH2 (III) and alkylated to give the N,N-dialkyl derivs. (IV). II were treated with a base to give [(MeO)nC6H5-n]2C:C(CN)Me (V), which were reduced to give [(MeO)nC6H5-n]2C:CMeCH2NH2 (VI). VI were alkylated to give the N,N-dialkyl derivs. (VII). Thus, 1,2-(MeO)2C6H4 was treated with I and AlCl3 3.5 hr at room temp. to give 30% II (n = 2), which (12 g) was reduced with Raney Ni in NH3-MeOH 2 hr at 50-60 atm and 80.degree. to give 10 g III (n = 2), which was refluxed with HCO2H and HCHO 8 hr to give 53.7% IV (n = 2, at positions 3 and 4). II (n = 2) was refluxed in NaOMe-MeOH 2.5 hr to give 87.6% V (n = 2), which (5.1 g) was reduced with Raney Ni to give 4.9 g VI (n = 2), which was refluxed with HCO2H and HCHO to give 61% VII (n = 2, at positions 3 and 4). Similarly prepd. were II-VII (n = 3, positions 2, 3, 4).

L7 ANSWER 27 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 76:153260 CA
TITLE: Arylalkylamine derivatives. III. Synthesis and pharmacological properties of N-(3,3-diarylpropyl)-N-aryl(diphenyl)alkylamines
AUTHOR(S): Mndzhoyan, A. L.; Markaryan, E. A.; Balayan, R. S.; Avakyan, O. M.; Tsatinyan, A. S.
CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Erevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1971), 24(9), 791-7
CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Five compds. of type I were prepd., in which R1, R2, R6, and R7 = H or MeO; R3 and R4 = H or Me; R5 = H or Ph; and n = 0 or 1. Compds. with R3 = H were prepd. by redn. of the amides with LiAlH4. Those with R3 = Me were prepd. by similar redn. of the Schiff bases. Sym-patholytic and adrenolytic properties were detd. on the sperm ducts of rats.

L7 ANSWER 28 OF 36 CA COPYRIGHT 2003 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 65:50767 CA
ORIGINAL REFERENCE NO.: 65:9521d-g
TITLE: Pharmacology of diphenylalkyl derivatives. I. Comparative studies of coronary dilator diphenylalkylamine derivatives
AUTHOR(S): Leszkovszky, G.; Tardos, L.; Erdely, Ilona; Harsanyi, K.
CORPORATE SOURCE: Chinoin Pharm. Works, Budapest
SOURCE: Acta Physiologica Academiae Scientiarum Hungaricae (1966), 29(3-4), 283-97
CODEN: APACAB; ISSN: 0001-6756
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The coronary dilator and other pharmacol. effects of 45 diphenylalkylamine derivs. (I) were reported for mice, rats, cats, and guinea pigs. Many of the compds. had coronary dilator activity comparable to that of prenylamine, and some, with identical potency to the reference compd., had certain other advantages such as lower hypertensive activity and a lower toxicity. For coronary dilator activity, the compd. must contain the secondary diphenylpropyl structure, with no primary or tertiary amino groups. Compds. contg. a secondary amino group must contain 2 aromatic groups linked to one end of the C chain, a propyl chain between the 2 aromatic rings and the amino N, and a basic N atom. The aralkyl group on the N must have a certain distance from the aromatic ring, usually 1 or 2 C atoms. Activity is also influenced by substituents on the aromatic rings of the diphenylpropylamine structure. Mols. in which another basic group is present in the N substituents are inactive. No correlation

existed between the spasmolytic and coronary dilator effects, or between the hypotensive and coronary dilator actions of the compds.

L7 ANSWER 29 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 61:61494 CA
ORIGINAL REFERENCE NO.: 61:10626d-e
TITLE: Diphenylalkanes
PATENT ASSIGNEE(S): Farbwerke Hoechst A.-G.
SOURCE: 8 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 959313		19640527	GB	
US 3177253		1965	US	

PRIORITY APPLN. INFO.: DE 19600130

AB 1-(m-Methoxyphenyl)-1-phenyl-3-aminopropane (24 g.) was hydrogenated at 60-5.degree. with 14 g. PhCH2Ac in 250 ml. Me2CHOH over Pd catalyst. Filtration, distn., and addn. of HCl gave 27.5 g. 1-phenyl-2-[3-(m-methoxyphenyl)-3-phenylpropyl]-aminopropane-HCl, m. 171-3.degree.. Also similarly prepd. were 1-phenyl-2- [3- (m- methoxyphenyl)-3-(p-methoxyphenyl)propyl]-aminopropane-HCl, m. 190-2.degree., 1-phenyl-2-[3-(m-methoxyphenyl)-1-phenylpropyl]aminopropane-HCl, m. 170-2.degree., 1-phenyl-2[3-(m-hydroxyphenyl)-3-phenylpropyl] aminopropane-HCl, m. 178-80.degree., 1-phenyl-2- [3-(m-hydroxyphenyl)-3-(p-hydroxyphenyl)propyl]aminopropane-HCl, m. 196-8.degree., 1-phenyl-2-[1-phenyl-1-(m-methoxyphenyl)propyl] aminopropane-HCl, m. 171-3.degree.. The compds. have an excellent activity on cardiac and general vascular circulation; 5-20 mg. caused rapid dilation of the coronary blood vessels.

L7 ANSWER 30 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 61:61495 CA
ORIGINAL REFERENCE NO.: 61:10626e-f
TITLE: Purification of aromatic amines
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: 8 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1361275		19640515	FR	
DE 1210876			DE	
GB 966812			GB	
US 3270058		1966	US	

PRIORITY APPLN. INFO.: GB 19620702

AB Mixed 2,4- and 2,6-tolylenediamines (I) are sepd. from impurities of o-diamines (II) by distn. in the presence of a boric acid or derivs. Thus, distg. 110.3 parts I contg. 5.5% II in the presence of 5.5 parts tetraboric acid (III) gives I, b760 280-2.degree., contg. 0.5% II. Instead of III orthoboric acid, tributyl borate, or phenylboronic acid (or its anhydride) may be used in the distn. pot.

L7 ANSWER 31 OF 36 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 54:56237 CA
ORIGINAL REFERENCE NO.: 54:10941d-i,10942a-d
TITLE: Elimination of acetic acid during decarboxylation of organic acids. II. Formation of .alpha.,.alpha.-diarylethylenes from .beta.,.beta.'-diarylbutyric acids

AUTHOR(S): Gogte, G. R.; Kasaralkar, D. Y.
CORPORATE SOURCE: Inst. Sci., Bombay
SOURCE: Journal of the University of Bombay, Science: Physical Sciences, Mathematics, Biological Sciences and Medicine (1958), 27(No. 3), 41-54
CODEN: JUBSAS; ISSN: 0368-4644
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C.A. 54, 8717b. The prepn. of variously substituted .beta.,.beta.-diarylbutyric acids and their behavior on distn. with lime was described. A mixt. of 32 cc. AcCH2CO2Et (I) and 31 cc. o-cresol Me ether (II) cooled to 0-5.degree., 200 cc. 70% H2SO4 added gradually with shaking, the mixt. left 8 hrs. at room temp., poured on crushed ice and the semisolid lump hydrolyzed by refluxing 2 hrs. with 160 cc. aq. 30% NaOH and 100 cc. MeOH gave 16 g. .beta.,.beta.-bis(4-methoxy-3-methylphenyl)butyric acid (III), m. 127.degree.; anilide m. 143.degree.; Et ester, m. 65.degree.. 2-Methoxy-4-methyl-.beta.-methylcinnamic acid (IV), m. 139.degree. (EtOH), obtained by an alk. hydrolysis of 4,7-dimethylcoumarin, similarly condensed with II and anisole, resp., gave .beta.-(2-methoxy-4-methylphenyl)-.beta.-(4-methoxy-3-methylphenyl)butyric acid (V), m. 120-1.degree. (anilide m. 139.degree.; Et ester m. 62.degree.), and .beta.-(2-methoxy-4-methylphenyl)-.beta.-(4-methoxyphenyl)butyric acid (VI), m. 162.degree. [anilide m. 136.degree.; Et ester m. 60.degree. (MeOH)]. Similarly, 20 g. 2-methoxy-5-methyl-.beta.-methylcinnamic acid (VII) (Auwers, C.A. 11, 2325) condensed with 24 cc. anisole gave 19 g. .beta.-(2-methoxy-5-methylphenyl)-.beta.-(4-methoxyphenyl)butyric acid (VIII), m. 163.degree.; anilide m. 153.degree.; Et ester b17 270.degree.. However, 10 g. VII condensed likewise with 6 cc. p-cresol gave 5 g. butyrolactone of .beta.-(2-methoxy-5-methylphenyl)-.beta.-(2-hydroxy-5-methylphenyl)butyric acid, m. 146.degree., 25 g. of which refluxed 2 hrs. with 200 cc. 30% NaOH soln. and subsequently methylated by adding 100 cc. Me2SO4 at 50.degree., refluxing 2 hrs., leaving overnight, and working up gave 15 g. .beta.,.beta.-bis(2-methoxy-5-methylphenyl)butyric acid (IX), m. 130.degree.; anilide m. 117.degree.; Et ester m. 60.degree.. The following butyrolactones and their corresponding butyric acids were similarly prepd. (g. substituted cinnamic acid, amt. phenol, g. substituted butyrolactone obtained, m.p., the corresponding butyric acid prepd., its m.p., m.p. of anilide, and m.p. of Et ester given): 30 g. IV, 33 cc. p-cresol, 22 g. butyrolactone of .beta.-(2-methoxy-4-methylphenyl)-.beta.-(2-hydroxy-5-methylphenyl)butyric acid (X), 160.degree., .beta.-(2-methoxy-4-methylphenyl)-.beta.-(2-methoxy-5-methylphenyl)butyric acid (XI) (10 g. from 25 g. X), 119.degree., 149.degree., 55.degree. (petr. ether); 30 g. VII, 33 cc. m-cresol, 18 g. butyrolactone of .beta.-(2-methoxy-5-methylphenyl).beta.-(2-hydroxy-4-methylphenyl)butyric acid, -, -, 155.degree., 149.degree., 55.degree.; 10 g. IV, 11 cc. m-cresol, 7 g. butyrolactone of .beta.-(2-methoxy-4-methylphenyl)-.beta.-(2-hydroxy-4-methylphenyl)butyric acid, 105.degree., .beta.,.beta.-bis(2-methoxy-4-methylphenyl)butyric acid (XII), 151.degree., 150.degree., 84.degree.; 10 g. VII, 10 g. resorcinol, 5 g. hydroxybutyrolactone of .beta.-(2-methoxy-5-methylphenyl)-.beta.-(2,4-dihydroxyphenyl)butyric acid (XIII), 220-1.degree., .beta.-(2-methoxy-5-methylphenyl)-.beta.-(2,4-dimethoxyphenyl)butyric acid (XIV) (8 g. from 15 g. of XIII), 116.degree., 165.degree., - (b10 240.degree.); 10 g. IV, 10 g. resorcinol, 10 g. hydroxybutyrolactone of .beta.-(2-methoxy-4-methylphenyl)-.beta.-(2,4-dimethoxyphenyl)butyric acid (XV), 190.degree. (methoxy deriv., m. 183.degree.), .beta.-(2-methoxy-4-methylphenyl)-.beta.-(2,4-dimethoxyphenyl)butyric acid (XVI), 116-17.degree., 132.degree., - (b15 160.degree.). Both, .beta.,.beta.-bis(p-methoxyphenyl)butyric acids, as well as .beta.-(p-methoxyphenyl)-.beta.-(o-methoxyphenyl)butyric acids, on distn. with lime at 3 mm., lost a mol. of AcOH and gave .alpha.,.alpha.-bis(substituted-phenyl)ethylenes, but .beta.,.beta.-bis(o-methoxyphenyl)butyric acids, under the same conditions, were demethylated to butyrolactones and Me esters of the corresponding butyric acids. The following were the results of distn. with lime of the various butyric acid

derivs. prepd. (butyric acid deriv., product obtained, m.p. given): III, .alpha.,.alpha.-bis(4-methoxy-3-methylphenyl)ethylene, 100.degree. (MeOH); V, .alpha.-(2-methoxy-4-methylphenyl)-.alpha.'-(4-methoxy-3-methylphenyl)ethylene, 104.degree. (MeOH); VI, .alpha.-(2-methoxy-4-methylphenyl)-.alpha.-(4-methoxyphenyl)ethylene, 142.degree. (MeOH); VIII, .alpha.-(2-methoxy-5-methylphenyl)-.alpha.-(4-methoxyphenyl)ethylene, 140.degree. (MeOH). IX, XI, XII, XIV, and XVI gave the butyrolactones and Me esters of the corresponding butyric acids. IV and VII distd. with lime at 4 mm. gave 4,7- and 4,6-dimethylcoumarins, resp. All compds., unless stated otherwise, were crystd. from 70% alc.

L7 ANSWER 32 OF 36 CAOLD COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: CA65:9521d CAOLD
TITLE: pharmacology of diphenylalkyl derivs. - (I) comparative studies of coronary dilator diphenylalkylamine derivs.
AUTHOR NAME: Leszkovszky, Gyorgy; Tardos, L.; Erdelyi, I.; Harsanyi, K.

L7 ANSWER 33 OF 36 CAOLD COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: CA61:10626e CAOLD
TITLE: purification of aromatic amines
PATENT ASSIGNEE: Imperial Chemical Industries Ltd.
DOCUMENT TYPE: Patent

	PATENT NO.	KIND	DATE
PI	FR 1361275		
	DE 1210876		
	GB 966812		
	US 3270058		1966

L7 ANSWER 34 OF 36 CAOLD COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: CA61:10626d CAOLD
TITLE: diphenylalkanes
PATENT ASSIGNEE: Farbwerke Hoechst A.-G.
DOCUMENT TYPE: Patent

	PATENT NO.	KIND	DATE
PI	GB 959313		
	US 3177253		1965

L7 ANSWER 35 OF 36 CAOLD COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: CA54:10941e CAOLD
TITLE: elimination of AcOH during decarboxylation of org. acids - (II) formation of .alpha.,.alpha.-diarylethylenes from .beta.,.beta.'-diarylbutyric acids
AUTHOR NAME: Gogte, G. R.; Kasaralkar, D. Y.

L7 ANSWER 36 OF 36 PHAR COPYRIGHT 2003 PJB on STN
TX NPS has discontinued development of NPS-846, a synthetic glutamate receptor blocker Araxin compound in favour of NPS-1506 (qv) (Company communication, Sep 1997). NPS-846 was in development for the potential treatment of acute and chronic pain as well as stroke and traumatic head injury (Scrip, 1995, 2028, 17). Araxin compounds inhibit glutamate-triggered calcium influx into nerve cells (Scrip, 1994, 1927, 11).

Preclinical

In preclinical studies, NPS-846 showed significant neuroprotective effects even when administered 2hr after the initial blood supply cut-off (Scrip, 1995, 2028, 17). In preclinical tests, the Araxin compounds have demonstrated broad efficacy as analgesics without the adverse effects associated with other glutamate blockers (Scrip, 1994, 1927, 11). Further methods of modulating glutamate receptor activity for indications such as muscle relaxation and cognition

L2 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 356782-29-1 REGISTRY
CN Benzenepropanamide, 2-hydroxy-3,4-dimethyl-.beta.-phenyl-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H29 N O2
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 210573-54-9 REGISTRY
CN .beta.-D-Glucopyranosiduronic acid, 4-methyl-2-[(1R)-3-[(1-methylethyl)amino]-1-phenylpropyl]phenyl (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H33 N O7
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 200429-71-6 REGISTRY
CN Phenol, 4-[3-amino-1-(3-fluorophenyl)propyl]-2-fluoro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 F2 N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 191233-21-3 REGISTRY
CN Guanidine, N-[3-(3,4-dichlorophenyl)-3-phenylpropyl]-N'-[3-(1H-imidazol-4-yl)propyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H25 Cl2 N5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 191233-02-0 REGISTRY
CN Guanidine, N-[3-(3,4-difluorophenyl)-3-(4-fluorophenyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H24 F3 N5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186495-56-7 REGISTRY
CN Benzenepropanamine, 3-fluoro-.gamma.-(3-fluorophenyl)-N,.alpha.-dimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenepropanamine, 3-fluoro-.gamma.-(3-fluorophenyl)-N,.alpha.-dimethyl-, (S)-
FS STEREOSEARCH
MF C17 H19 F2 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144478-00-2 REGISTRY
CN Guanidine, N-[3,3-bis(3-fluorophenyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)
MF C22 H25 F2 N5 . 2 Cl H
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS

(*File contains numerically searchable property data)

CRN (191233-28-0)



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144452-04-0 REGISTRY
CN Benzenepropanamine, 3-chloro-.gamma.-(3-fluorophenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 Cl F N
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144451-98-9 REGISTRY
CN Benzenepropanamine, 3-fluoro-.gamma.-(3-fluorophenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NPS 846
FS 3D CONCORD
MF C15 H15 F2 N
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, PHAR, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144451-90-1 REGISTRY
CN Benzenepropanamine, 3-fluoro-.gamma.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H16 F N
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144451-81-0 REGISTRY
CN Benzenepropanoic acid, .alpha.-(aminocarbonyl)-3-chloro-.beta.-(3-chlorophenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H13 Cl2 N O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144451-00-3 REGISTRY
CN Guanidine, N-[3-(3,4-difluorophenyl)-3-(3-fluorophenyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H24 F3 N5
CI COM
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 134220-32-9 REGISTRY
CN Phenol, 4-[1-[(1-methyl-3-phenylpropyl)amino]ethenyl]-2-[3-[(1-methyl-3-phenylpropyl)amino]-1-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C38 H44 N2 O
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 123936-52-7 REGISTRY
CN Hydrocinnamanilide, 2,4-dimethoxy-.beta.-(6-methoxy-m-tolyl)-.beta.-methyl- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H29 N O4
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 15 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 119433-48-6 REGISTRY
CN .alpha.-D-Glucopyranosiduronic acid, 4-[3-[(1,1-dimethylethyl)amino]-1-phenylbutyl]-2-methoxyphenyl, [S-(R*,R*)]- (9CI) (CA INDEX NAME)
MF C27 H37 N O8
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 97153-02-1 REGISTRY
CN Phenethylamine, N-[3-(m-methoxyphenyl)-3-phenylpropyl]-.alpha.-methyl-

(7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H29 N O
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 17 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 95956-75-5 REGISTRY
CN Phenol, 3,4'-[3-[(.alpha.-methylphenethyl)amino]propylidene]di- (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H27 N O2
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 18 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 89036-00-0 REGISTRY
CN Phenol, 2-methoxy-6-[3-[(1-methyl-3,3-diphenylpropyl)amino]-1-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)
MF C32 H35 N O2 . Cl H
LC STN Files: CA, CAPLUS
CRN (344880-85-9)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 89028-00-2 REGISTRY
CN Benzenepropanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-hydroxy-3-methoxy-.beta.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H29 N O5
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 88407-46-9 REGISTRY
CN Phenol, 4-methyl-2-[3-[(1-methyl-2-phenylethyl)amino]-1-phenylpropyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H29 N O
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 72371-98-3 REGISTRY
CN Benzenepropanoic acid, 3-(1,1-dimethylethyl)-.beta.-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-4-hydroxy-.beta.-methyl-, 2-[4-[[[bis[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]oxy]methyl]-1,6-bis(octadecyloxy)-2,5,7-trioxa-1,6-diphosphapentacos-1-yl]hydrazide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C111 H192 N2 O12 P2
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 70823-68-6 REGISTRY
CN Benzenepropanamine, .alpha.,3-dimethyl-.gamma.-(3-methylphenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)
MF C18 H23 N . C2 H2 O4
LC STN Files: CA, CAPLUS

CM 1

CRN 70823-67-5
CMF C18 H23 N



CM 2

CRN 144-62-7
CMF C2 H2 O4



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 59484-98-9 REGISTRY
CN Benzenepropanamine, .gamma.-(3,4-dimethoxyphenyl)-3,4-dimethoxy-.beta.-(methoxymethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H29 N O5
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 36318-44-2 REGISTRY
CN Benzenepropanamine, 3,4-dimethoxy-N-(1-methyl-3,3-diphenylpropyl)-.gamma.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C33 H37 N O2
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 5966-37-0 REGISTRY
CN Benzenepropanamine, N-[2-(3,4-dimethoxyphenyl)-1-methylethyl]-3-methyl-.gamma.-phenyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenethylamine, 3,4-dimethoxy-.alpha.-methyl-N-(3-phenyl-3-m-tolylpropyl)- (7CI, 8CI)
FS 3D CONCORD
MF C27 H33 N O2
LC STN Files: CA, CAOLD, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> 144452-04-0
L3 1 144452-04-0
(144452-04-0/RN)

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.